EXTON, Pa. (AP) — The drugmaker Adolor Corp. said Thursday it will eliminate about 45 jobs, or 28 percent of its work force, to cut costs and will focus on developing it most promising drugs. Adolor said the moves will reduce annual spending by about $12 million. It said it will focus on its constipation drug Entereg and products which are in the later stages of clinical development. The company said it is putting fewer resources into early stage drug candidates. Entereg, its only approved drug, is intended to treat constipation following abdominal surgery. It was launched last year, and sales totaled $1.2 million. Adolor markets the drug through a partnership with GlaxoSmithKline PLC of London.
